⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12257056 | 0.72 | — | — | |
| SCHEMBL13462431 | 0.70 | — | — | |
| SCHEMBL1465118 | 0.70 | — | — | |
| SCHEMBL859560 | 0.70 | — | — | |
| SCHEMBL31569499 | 0.69 | FBP1 (0.37) | — | |
| SCHEMBL13993965 | 0.68 | — | — | |
| SCHEMBL20551417 | 0.68 | — | — | |
| SCHEMBL6296384 | 0.65 | TYR (0.31) | — | |
| SCHEMBL13321594 | 0.65 | — | — | |
| SCHEMBL19932541 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2024217500-A1 | ISOQUINOLINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2024-10-24 | — | — | WO | disclosed |
| US-20240352037-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2024-10-24 | — | — | US | disclosed |
| US-12054498-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118359538-A | Isoquinoline compound, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230107663-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2023-04-06 | — | — | US | disclosed |
| CN-115916754-A | Heteroaromatic macrocyclic ether chemotherapeutic agents | 纽威伦特公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4137484-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-22 | — | — | EP | disclosed |
| US-20100004237-A1 | 2-Amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidin-5-ones | MACHAKEWSKI TIMOTHY D | 2010-01-07 | — | — | US | disclosed |
| US-20100004237-A1 | 2-Amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidin-5-ones | MACHAKEWSKI TIMOTHY D | 2010-01-07 | — | — | US | disclosed |
| US-20100004237-A1 | 2-Amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidin-5-ones | MACHAKEWSKI TIMOTHY D | 2010-01-07 | — | — | US | disclosed |
| CN-101287734-A | 2-amino-7, 8-dihydro-6H-pyrido [4, 3-d ] pyrimidin-5-ones | NOVARTIS AG (CH) | 2008-10-15 | — | — | CN | disclosed |
| EP-1928875-A1 | 2-AMINO-7,8-DIHYDRO-6H-PYRIDOÝ4,3-D¨PYRIMIDIN-5-ONES | Novartis AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | CHIRON CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | CHIRON CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123546-A1 | 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones | CHIRON CORPORATION | 2007-05-31 | — | — | US | disclosed |
| WO-2007041362-A1 | 2-AMINO-7,8-DIHYDRO-6H-PYRIDO[4,3-D] PYRIMIDIN-5-ONES | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041362-A1 | 2-AMINO-7,8-DIHYDRO-6H-PYRIDO[4,3-D] PYRIMIDIN-5-ONES | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |